Skip to main content
Pei Lin, MD, Pathology, Houston, TX

PeiLinMD

Pathology Houston, TX

Hematopathology, Anatomic Pathology, Clinical Pathology

professor

Dr. Lin is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Lin's full profile

Already have an account?

  • Office

    1515 Holcombe Blvd
    Houston, TX 77030
    Phone+1 713-792-6161

Education & Training

  • University of Texas M D Anderson Cancer Center
    University of Texas M D Anderson Cancer CenterFellowship, Hematopathology, 1999 - 2000
  • Yale-New Haven Medical Center
    Yale-New Haven Medical CenterResidency, Pathology-Anatomic and Clinical, 1995 - 1999
  • Nanjing Medical University
    Nanjing Medical UniversityClass of 1982

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2014 - 2026
  • TX State Medical License
    TX State Medical License 2003 - 2025
  • MI State Medical License
    MI State Medical License 1999 - 2006
  • AR State Medical License
    AR State Medical License 2000 - 2002
  • American Board of Pathology Anatomic Pathology & Clinical Pathology
  • American Board of Pathology Hematology

Publications & Presentations

PubMed

Journal Articles

  • Original Contribution Utility of JAK2 V617F Allelic Burden in Distinguishing Chronic Myelomonocytic Leukemia from Primary Myelofibrosis with Monocytosis☆  
    Shaoying Li, L Jeffrey Medeiros, Pei Lin, Srdan Verstovsek, ScienceDirect
  • Original Contribution IgM Plasma Cell Myeloma in the Era of Novel Therapy: A Clinicopathologic Study of 17 Cases☆  
    Shaoying Li, Pei Lin, L Jeffrey Medeiros, Guilin Tang, ScienceDirect

Abstracts/Posters

  • A Multicenter Phase II Single Arm Trial of Isatuximab in Patients with High Risk Smoldering Multiple Myeloma (HRSMM)
    Pei Lin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • A Multicenter Phase II Single Arm Trial of Isatuximab in Patients with High Risk Smoldering Multiple Myeloma (HRSMM)
    Pei Lin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Press Mentions

  • Parkinsons Disease Linked with Most Cancers in Taiwan
    Parkinsons Disease Linked with Most Cancers in TaiwanJune 19th, 2015
  • Parkinson’s Disease Linked with Most Cancers in Taiwan
    Parkinson’s Disease Linked with Most Cancers in TaiwanJune 19th, 2015